Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic toll-like receptor 4 agonist formulated in an emulsion

Infection and Immunity

Volumn 79, Issue 9, 2011, Pages 3492-3500

  Lumsden, Joanne M ^a   Pichyangkul, Sathit ^b   Srichairatanakul, Utaiwan ^b   Yongvanitchit, Kosol ^b   Limsalakpetch, Amporn ^b   Nurmukhambetova, Saule ^a   Klein, Jennifer ^a   Bertholet, Sylvie ^c   Vedvick, Thomas S ^c   Reed, Steven G ^c   Sattabongkot, Jetsumon ^b   Bennett, Jason W ^a   Polhemus, Mark E ^a   Ockenhouse, Christian F ^a   Howard, Randall F ^c   Yadava, Anjali ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOPYRANOSYLLIPID A; IMMUNOGLOBULIN G; INTERLEUKIN 2; MALARIA VACCINE; RECOMBINANT PROTEIN VMP001; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; DRUG SAFETY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EMULSIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; LIPID A; MACACA MULATTA; MALARIA VACCINES; MALARIA, VIVAX; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 80052316348     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05257-11     Document Type: Article

References (35)

1. Anderson, R. C., et al. 2010. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B Biointerfaces 75:123-132.
2. Baldwin, S. L., et al. 2009. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27:3063-3071.
3. Baldwin, S. L., et al. 2009. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27:5956-5963.
4. Bell, B. A., et al. 2009. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 27:1448-1453.
5. Bertholet, S., et al. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27:7036-7045.
6. Bertholet, S., et al. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2:53ra74.
7. Charoenvit, Y., et al. 1991. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251:668-671.
8. Cohen, J., V. Nussenzweig, R. Nussenzweig, J. Vekemans, and A. Leach. 2010. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccin. 6:90-96.
9. Coler, R. N., et al. 2010. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5:e13677.
10. Garcon, N., P. Chomez, and M. Van Mechelen. 2007. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6:723-739.
11. Garcon, N., D. G. Heppner, and J. Cohen. 2003. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines 2:231-238.
12. Gauduin, M. C. 2006. Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses. Methods 38: 263-273.
13. Gauduin, M. C., et al. 2004. Optimization of intracellular cytokine staining for the quantitation of antigen-specific CD4+ T cell responses in rhesus macaques. J. Immunol. Methods 288:61-79.
14. Gordon, D. M., et al. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1576-1585.
15. Guerra, C. A., et al. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:e774.
16. Herrera, S., et al. 1997. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol. 19:161-170.
17. Kester, K. E., et al. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malarianaive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200:337-346.
18. Ketloy, C., et al. 2008. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet. Immunol. Immunopathol. 125:18-30.
19. Mehlhop, E., et al. 2002. Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses. J. Immunol. Methods 260:219-234.
20. Moorthy, V. S., and W. R. Ballou. 2009. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J. 8:312.
21. Nardin, E., et al. 1991. T cell epitopes of the circumsporozoite protein of Plasmodium vivax. Recognition by lymphocytes of a sporozoite-immunized chimpanzee. J. Immunol. 146:1674-1678.
22. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
23. Pichyangkul, S., et al. 2008. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun. 76:229-238.
24. Pitcher, C. J., et al. 2002. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168:29-43.
25. Raman, V. S., et al. 2009. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect. Immun. 77:5623-5630.
26. Roestenberg, M., et al. 2008. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3:e3960.
27. Ruprecht, C. R., and A. Lanzavecchia. 2006. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36:810-816.
28. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258.
29. Stewart, V. A., et al. 2006. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24:6483-6492.
30. Stoute, J. A., et al. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336:86-91.
31. Sun, P., et al. 2003. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J. Immunol. 171: 6961-6967.
32. Vanderberg, J. P., and U. Frevert. 2004. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34:991-996.
33. Wu, Y., et al. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with Montanide ISA 51. PLoS One 3:e2636.
34. Yadava, A., et al. 2007. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect. Immun. 75:1177-1185.
35. Yang, C., et al. 1997. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Vaccine 15:377-386.